Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.47 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130730 | 0.93 | MAPT (0.45) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL5094616 | 0.88 | HRH3 (0.46) | HSP90AA1HRH3KCNH2 | |
| SCHEMBL6746929 | 0.87 | PDK1 (0.52) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL3919089 | 0.83 | THRB (0.43) | MAPT | |
| SCHEMBL11900837 | 0.83 | MAPT (0.46) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL3991443 | 0.83 | THRB (0.38) | HSP90AA1HSP90AB1KCNH2 | |
| SCHEMBL3995701 | 0.82 | BRD4 (0.43) | HSP90AA1PDK1HSP90B1HSP90AB1HRH3 | |
| SCHEMBL3995567 | 0.82 | HSP90AA1 (0.41) | HSP90AA1MAPTHSP90B1TRAP1 | |
| SCHEMBL3920824 | 0.81 | THRB (0.39) | HSP90AA1MAPTHSP90B1TRAP1HSP90AB1 | |
| SCHEMBL5103376 | 0.81 | HSP90AA1 (0.45) | HSP90AA1MAPTHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | claimed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | claimed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | claimed |
| EP-2038262-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | claimed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| EP-2038262-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2038262-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885MAPT 2927/4885PDK1 1567/4885 |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885MAPT 2927/4885PDK1 1567/4885 |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885MAPT 2927/4885PDK1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.